What is Leerink Partnrs’ Forecast for ARWR FY2025 Earnings?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Stock analysts at Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for Arrowhead Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 18th. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earnings per share of $0.23 for the year, down from their previous forecast of $0.37. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals’ Q4 2025 earnings at $0.06 EPS, FY2026 earnings at ($0.98) EPS, FY2027 earnings at ($2.45) EPS and FY2028 earnings at ($1.93) EPS.

Other research analysts also recently issued reports about the company. Royal Bank Of Canada upped their target price on Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the stock an “outperform” rating in a research note on Wednesday. Morgan Stanley boosted their price objective on Arrowhead Pharmaceuticals from $29.00 to $45.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 12th. The Goldman Sachs Group upped their target price on Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the company a “neutral” rating in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Piper Sandler boosted their price target on shares of Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an “overweight” rating in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $48.22.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $40.45 on Friday. Arrowhead Pharmaceuticals has a twelve month low of $9.57 and a twelve month high of $43.69. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. The company has a market cap of $5.59 billion, a PE ratio of -31.60 and a beta of 1.27. The company’s 50 day moving average is $36.95 and its 200 day moving average is $24.56.

Institutional Trading of Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. iSAM Funds UK Ltd acquired a new position in Arrowhead Pharmaceuticals in the third quarter valued at about $29,000. Virtus Advisers LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at approximately $34,000. Salomon & Ludwin LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $34,000. Nisa Investment Advisors LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 75.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 1,308 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $52,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider James C. Hamilton sold 20,000 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total value of $700,000.00. Following the transaction, the insider owned 212,122 shares of the company’s stock, valued at $7,424,270. This represents a 8.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 50,000 shares of company stock valued at $1,525,000 in the last quarter. 4.30% of the stock is owned by insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.